Event 2023

WEEK OF SEPTEMBER 18, 2023

The Future of AI and Robotics in Healthcare

Japan Healthcare Week, featuring Conference Events in Nagoya (Sep. 19) and Tokyo (Sep. 21)

Japan Week Event on September 21, 2023


*Invitation Only Event
WHEN

Tokyo Executive Symposium
Sep 21, 2023
1:00pm-5:35pm

Reception: 5:45-6:45pm

WHERE

Tokyo Executive Symposium

Nihonbashi Life Science Hub (Link)

後援 Supporting Organizations
— HEALTHCARE SYMPOSIUM AGENDA —
Tokyo, September 21, 2023

12:30 P.M. – 1:00 P.M.

REGISTRATION

1:00 P.M. – 1:15 P.M.

OPENING OF THE SYMPOSIUM, WELCOME REMARKS

Steve Pollock assumed the position of President of Japan Society of Northern California on August 23, 2022. Previously a JSNC Board member, Mr. Pollock has been actively involved with a number of the Society’s signature initiatives, including starting JSNC’s operations in Japan in 2016, leading the corporate membership committee, and serving on the steering committee for the annual Innovation Awards.

After graduating from Jichi Medical University, he began practicing general medicine in the rural areas of Japan. Fumiaki joined the Department of Cardiovascular Medicine at Stanford University in 2001, and was closely involved with the R&D, animal studies, and clinical studies of many medical device startups. He is also actively involved in projects with the US and Japanese regulatory agencies working to create an effective cross-border medical device eco-system. Fumiaki has also been an advisory faculty for the Stanford Biodesign Program since 2014. He is deeply involved with the development of the Japan Biodesign Program and is working diligently to establish a Silicon Valley-like medical device eco-system in Japan.

1:15 P.M. – 2:00 P.M.

KEYNOTE PRESENTATION 1: THE AI REVOLUTION IN HEALTHCARE

Dr. Khizer Khaderi is a Clinical Associate Professor at the Byers Eye Institute at Stanford University. Khaderi is the Director/Founder of the Stanford Human Perception Laboratory (HPL) and the Stanford Vision Performance Center (VPC). He also serves as faculty at the Stanford Institute for Human-Centered AI and the Wu Tsai Human Performance Alliance (HPA).

Bio

2:00 P.M. – 2:45 P.M.

KEYNOTE PRESENTATION 2: INNOVATION FOR THE FUTURE OF ROBOTIC HEALTHCARE

Frank Litvack, M.D., FACC. Dr. Litvack is a native of Canada. He completed medical school and residency at McGill University in Montreal and a Cardiovascular Fellowship at Cedars-Sinai Medical Center in Los Angeles, where he subsequently became co-director of the Cardiovascular Intervention Center and Professor of Medicine at UCLA. There he led a prominent clinical and research program known for its excellence in innovation, care and leadership in Translational Medicine.

Read more here.

2:45 P.M. – 3:00 P.M.

BREAK

3:00 P.M. – 4:00 P.M.

PANEL DISCUSSION ON DRIVING HEALTHCARE INNOVATION THROUGH US-JAPAN PARTNERSHIPS

Glenn Snyder is a Principal with Deloitte Consulting, LLP. He leads Deloitte’s Medical Technology practice. Glenn has been serving the life sciences and healthcare industry as a consultant since 1989 and has been with Deloitte since 1995, tackling issues and opportunities across the healthcare value chain over the course of his career, including the payor and provider sectors.

Glenn holds a Master of Business Administration in Finance and Strategic Management from the Wharton School of the University of Pennsylvania, a Master of Science in Engineering from the University of Southern California, and a Bachelor of Science in Engineering from Cal Poly, San Luis Obispo.

Bio

Tom Kluz serves as the Managing Partner at Niterra Ventures, spearheading global investments on behalf of Niterra Co., LTD across medical, energy & environment, and mobility sectors. While he oversees investment endeavors in all these domains, Tom is particularly renowned for his deep expertise in healthcare. This distinction stems from a decade-long stint as the Head of Global Healthcare Investing at Qualcomm Ventures and a pivotal role at Providence Ventures.

Bio

Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati and a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.

Bio

He received the B.S. degree, the M.S. degree in information and communication engineering, and the Ph.D. degree in electronic engineering, all from the University of Tokyo, in 1998, 2000, and 2003, respectively. From Apr. 2003 to Jun. 2006, he was an assistant professor at Department of Orthodontics and Dentofacial Orthopedics, Graduate School of Dentistry, Osaka University. He became a lecturer at Department of Orthodontics and Dentofacial Orthopedics, Osaka University Dental Hospital in Jul. 2006.

Bio

Yuki Sugano is a Senior Director at Stryker Japan K.K. where she leads Corporate Strategy and
Marketing.


Yuki has been with Stryker since 1996 and has held progressively senior roles in marketing that span multiple business units. Between 2007 and 2011, Yuki served as Global Product Manager for Trauma and Extremities in Kiel, Germany. Upon her return to Japan, she was appointed Director of Marketing for Joint Replacement. She was appointed to her role in 2021 and now leverages her decades of marketing experience to support company-wide marketing excellence.

Bio

4:00 P.M. – 5:20 P.M.

EARLY STAGE AND PRIVATE COMPANY PRESENTATIONS

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Elton represents both public and private enterprises as their outside general counsel and serves as a key strategic advisor from their inception throughout their life cycle. He advises on complex venture capital and corporate finance transactions, corporate law and governance, mergers and acquisitions, and public offerings. 

Bio

Javier Evelyn is the CEO and Founder of Alerje, a digital health company specializing in emergency medicine. Alerje is dedicated to improving the lives of over 220 million families worldwide living with food allergies by creating innovative solutions that help them make the most of every moment. In addition to being a founding member of MedTech Color, Javier serves on the boards of both the Accelerate Blue Fund at the University of Michigan and MATTER Health.

Bio

Company Website

Ben Toker is a serial entrepreneur and technologist with strong commercial acumen and a focus on digital health.

He is currently the Co-Founder and CTO of Amaros – an AI-powered software platform to accelerate clinical studies and enable earlier treatment for vision care. Amaros predicts the progression of eye diseases based on industry-first Machine Learning algorithms that holistically integrate medical imaging, genomics, health data, and clinical studies.

Bio

Company Website

Dana Cooney joined Digital Diagnostics as the VP of International Sales where she is responsible for developing and executing global commercialization plans for both on market and pipeline products, including partner relationships, licensee contracts, regulatory guidelines, adherence to country specific data management laws and regulations, KOL relationships, operations management, and reimbursement activities.

Bio

Company Website

Eirini Schlosser is the Founder and CEO of Dyania Health, a fast-growing technology company focused on training natural language understanding (large language models) for medical grade performance in clinical research. She is leading a team of NLP Applied Scientists and Physicians, bridging computational acumen and medical expertise, to build Dyania Health’s Synapsis AI, an end-to-end systems adapted for various clinical support use cases.

Bio

Company Website

Mr. Kim is a seasoned entrepreneur and strategist with various experiences in the healthcare sector.
Prior to taking head of Ficor, he has provided strategy and guidance to numerous companies doing
cross-border businesses, especially with the Middle East for almost 30 years.

Bio

Company Website

Rodolfo Rohr is co-founder and CEO of LarmorBIO, an early stage Massachusetts Institute of Technology (MIT) spin-off pioneering a new class of AI based magnetic resonance technology for rapid, live, cellular oxidative stress measurements. It’s long term vision is to enable precision medicine at scale. Mr. Rohr is an electrical engineer and entrepreneur with 15+ years of C-level roles in life sciences and medical devices, including at Interactive Motion Technologies.

Bio

Company Website

Dr. Krawczyk is an advisor and investor with Level 42 AI. He obtained his PhD in Medicinal Chemistry at the University of Michigan at Ann Arbor with Dr. Leroy Townsend. After joining Gilead Sciences shortly after its founding, he worked on antisense research, aptamers, and small molecule antivirals. His research led to the publication of over 40 journal articles and patent applications.

Bio

Company Website

 

Dean has over 25 years of experience in launching and growing brands in the areas of: medical devices, OTC health/wellness products, digital health apps, medical/pharmaceutical therapeutics, life science start-ups as well as Fortune 25 companies. Dean is the Founder & CEO of Mind Machine LLC, a strategic marketing and advertising agency in Silicon Valley. Before that role, Dean was a business advisor where he counseled life science and CPG companies regarding commercialization, market research, messaging, fundraising, crafting partnerships, building teams and developing products.

Bio

Company Website

Dr Rahaf Al Assil is the founder, Chair of the board, and the CEO of PantridgeDTell Corporations. Dr Al Assil is a clinician scientist and an entrepreneur who has about 15 years of clinical practice in acute cardiac care and cardiometabolic medicine in Canada and oversees and just over 5 years in cardiac arrest academic and industrial research. She completed her clinical grad studies from Damascus university in 2008. She was first board certified in internal medicine in 2014 and is preparing for her next Canadian board certification in 2024. Dr Assil completed a Master of Health Sciences/Clinical Methodology in 2019 and a research fellowship in cardiac arrest and resuscitation in 2021 form the University of British Columbia.

Bio

Company Website

Kirk Zeller is a 25+ year veteran of the medical device industry with extensive global commercial experience having lived, worked, and studied in US, Europe, and Asia. Kirk has leveraged his Silicon Valley start-up experience and start-up focused research to start several companies including Progressive NEURO, Inc, ATS.Solutions, and MedMarket Access. Kirk is the Chief Business Officer for Radux Devices, LLC. Kirk currently serves on the boards of Radux Devices, MedMarket Access, and Progressive NEURO, Inc. Kirk received an award and was recognized by United States Congressman Adrian Smith for his entrepreneurial endeavors during COVID.

Bio

Company Website

Mr. Lonsinger brings 25 years of medical sales and operations management to ViOptix. Mark comes from Philips Medical Systems, formerly ADAC Laboratories, where he was in charge of operations for the company’s nuclear medicine business. He previously was responsible for the sales operations and supply chain for the radiation therapy planning (RTP) and the positron emission tomography (PET) businesses. He has also held positions in manufacturing, project management, and finance. He was part of the ADAC team that won the Malcolm Baldrige award for quality assurance in 1996. Mark holds a BA in Economics from the University of California at Berkeley.

Bio

Company Website

5:20 P.M. – 5:35 P.M.

CONFERENCE WRAP-UP

After graduating from Jichi Medical University, he began practicing general medicine in the rural areas of Japan. Fumiaki joined the Department of Cardiovascular Medicine at Stanford University in 2001, and was closely involved with the R&D, animal studies, and clinical studies of many medical device startups. He is also actively involved in projects with the US and Japanese regulatory agencies working to create an effective cross-border medical device eco-system. Fumiaki has also been an advisory faculty for the Stanford Biodesign Program since 2014. He is deeply involved with the development of the Japan Biodesign Program and is working diligently to establish a Silicon Valley-like medical device eco-system in Japan.

5:45 P.M. – 6:45 P.M.

RECEPTION + SOCIAL NETWORKING